Dynavax stock news. 94% below its 52-week high of $15.

Dynavax stock news LLC and will initially receive approximately 6. Oct 28, 2024 · Shares of Dynavax Technologies Corp (DVAX, Financial) surged 4. 5 days ago · See the latest Dynavax Technologies Corp stock price (DVAX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. La empresa llevará a cabo una conferencia telefónica y una transmisión en línea a las 4:30 p. According to Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase. 74. 57 billion, a price-to-earnings ratio of 70. 68% upside potential. 0% Convertible Senior Notes due 2030, comprising an exchange for approximately $185 million of existing 2. D. Oct 29, 2024 · Dynavax Technologies (DVAX) has implemented a -duration stockholder rights plan in response to Deep Track Capital's recent accumulation of 13. 18 hours ago · William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. SEC Filings. Mar 6, 2025 · The conversion price of the New Notes will initially be $18. This is because this security in the Medical - Biomedical and Genetics space is seeing Feb 6, 2025 · EMERYVILLE, Calif. All News Press Releases . Oct 29, 2024 · Dynavax’s board has adopted a limited-duration stockholder rights plan, effective immediately. 76% in mid-day trading on Oct 28. Dynavax Technologies Corp (DVAX) Stock Price and Basic Information | MarketWatch Get Free Updates Join thousands of investors who get the latest news, insights and top rated picks from StockNews. Learn more about DVAX stock here. 20 on Monday. 1 million shares, with an aggregate value representing approximately 80% of the $100 million paid to Goldman Sachs & Co. Track Dynavax Technologies Corp. The company has a market cap of $1. 00 to $12. Get the latest Dynavax Technologies Corporation DVAX detailed stock quotes, stock data, Real-Time ECN, charts, stats and Nov 9, 2024 · The average DVAX stock price target is $27. 2 days ago · Dynavax Technologies has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based off last year's report dates. The latest Dynavax Technologies stock prices, stock quotes, news, and DVAX history to help you invest and trade smarter. 32. 23. 01 following its latest third-quarter results. DVAX Stock Data Market Cap 1. 1 day ago · Dynavax Technologies Stock Performance. Nov 10, 2024 · Shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) will be pleased this week, given that the stock price is up 10% to US$13. Since the start of the year the stock price has inched up 1. Mar 27, 2025 · Stay up-to-date on Dynavax Technologies Corporation Common Stock (DVAX) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. View live Dynavax Technologies Corporation chart to track its stock's price action. 11 Get real-time stock quotes, news, price and financial information for Dynavax Technologies Corp (DVAX:NASDAQ) from CNBC. Mar 10, 2025. 20% above its 52-week low of $9. Find everything from its Valuation, Future Growth, Past Performance and more. 25, before settling at $11. (DVAX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 05. 00 from the previous $15. Catching up: HEPLISAV-B 2023 revenue was $213 million. Update 5pm: Adds Dynavax response. , Feb. Find the latest Dynavax Technologies Corporation (DVAX) stock discussion in Yahoo Finance's forum. 4 days ago · DVAX | Complete Dynavax Technologies Corp. The company is set to issue $225 million in 2. Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. 4 days ago · Should You Buy or Sell Dynavax Technologies Stock? Get The Latest DVAX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. 67, implying 112. 47% and it climbed 6. 79 on Friday. HEPLISAV-B ha raggiunto un fatturato annuo record di 268 milioni di dollari, con una crescita del 26% rispetto all'anno precedente, e un fatturato nel quarto trimestre di 71 milioni di dollari, in aumento del 39% rispetto al quarto trimestre del 2023. View real-time stock prices and stock quotes for a full financial overview. Feb 25, 2025 · DVAX Latest News. 65 on Friday. has a fifty-two week low of $9. , April 3, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today filed its preliminary proxy materials with the Securities and Exchange Commission ("SEC") in connection with its upcoming Annual Meeting of Stockholders ("the 2025 Find the latest Dynavax Technologies Corporation (DVAX) stock quote, history, news and other vital information to help you with your stock trading and investing. Find the latest Dynavax Technologies Corporation (DVAX) stock quote, history, news and other vital information to help you with your stock trading and investing. Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase. 1 day ago · Dynavax Technologies Stock Performance NASDAQ:DVAX opened at $12. NasdaqGS - Delayed Quote Recent News: DVAX View More . Emilio Emini, Ph. 47M. Share this article which represents a conversion premium of 30% over the closing price of Dynavax's common stock on March 5, 2025. Dynavax Announces $100 Million Accelerated Share Repurchase Program. Company Overview Dynavax Technologies Corporation (DVAX) stands as a commercial-stage biopharmaceutical company that is dedicated to developing and commercializing Sep 24, 2021 · Get the latest Dynavax Technologies Corporation (DVAX) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. com. 6% Feb 24, 2025 · Dynavax Technologies (DVAX) closed the last trading session at $13. Feb 19, 2025 · Feb. Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2. 63. Mar 2, 2025 · Dynavax Technologies Price Performance. UU. 6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set Aug 6, 2024 · Analyst Roy Buchanan from JMP Securities reiterated a Buy rating on Dynavax (DVAX – Research Report) and keeping the price target at $29. May 10, 2024 · Dynavax's stock is down 20% since then. Mar 6, 2025 · Dynavax Technologies Corp. 6 days ago · Analyst Forecast. 50% Feb 2, 2022 · A list of the latest Dynavax Technologies Corp. Finally, The Goldman Sachs Group cut Dynavax Technologies from a "neutral" rating to a "sell" rating and lowered their price objective for the stock from $15. The company will issue $225 million in 2. Dynavax Technologies' Heplisav-B vaccine continues to gain market share, driving solid revenue growth. 01M. View (DVAX) real-time stock price, chart, news, analysis, analyst reviews and more. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. Deep Track Capital Sends Letter to Dynavax Technologies’ Board of Directors. 3 days ago · DVAX, Dynavax Technologies - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Feb 19, 2025 · Dynavax Technologies (DVAX) has responded to Deep Track Capital's nomination of four board candidates, highlighting its strong execution and value creation strategy. 09. Jan 27, 2025 · Dynavax Technologies (DVAX) a annoncé des changements significatifs au sein de son conseil d'administration dans le cadre de son programme de renouvellement en cours. 3 days ago · Get the latest Dynavax Technologies Corporation (LON:0IDA) stock price with financials, statistics, dividends, charts and more. The Mar 10, 2025 · Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock. Nov 7, 2024. On Tuesday, Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) stock from Neutral to Sell, adjusting the price target downward to $12. We would like to show you a description here but the site won’t allow us. --(BUSINESS WIRE)-- Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14. Learn more on DVAX's earnings history. 6 %. 6 days ago · View Dynavax Technologies Corporation DVAX investment & stock information. Mar 5, 2025 · In other recent news, Dynavax Technologies reported its fourth-quarter earnings, with revenues of $71. Mar 6, 2025 · Dynavax Technologies (DVAX) has announced a significant debt refinancing initiative and share repurchase program. L'entreprise a confirmé son objectif de revenus nets pour Real time Dynavax Technologies (DVAX) stock price quote, stock graph, news & analysis. The company reported record HEPLISAV-B revenue in 2024 with 26% year-over-year growth and expects to achieve 60% market share by 2030. 4 days ago · EMERYVILLE, Calif. 00. 33, gaining 4. com! 6 days ago · Research Dynavax Technologies' (Nasdaq:DVAX) stock price, latest news & stock analysis. 20 (-1. Share your opinion and gain insight from other stock traders and investors. 3 days ago · Latest news: Dynavax Technologies Corporation Dynavax Technologies Corporation Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-11-2025 10:00 AM Mar. 22, up from its previous close of $10. Stay ahead with Nasdaq. Results look Dynavax (DVAX) Company Description: Dynavax Technologies Corp. News - DVAX Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions. Nov 11, 2024. Dynavax (DVAX) Company Description: Dynavax Technologies Corp. 71 billion, a PE ratio of 76. Stay updated on market trends for DVAX. (), Thursday announced a debt refinancing and common stock share repurchase. 6% Mar 6, 2025 · News provided by Dynavax Technologies Mar 06, 2025, 06:00 ET . The plan grants stockholders one preferred share purchase right per common share as of November 8, 2024. Share your ideas and get valuable insights from the community of like minded traders and investors A high-level overview of Dynavax Technologies Corporation (DVAX) stock. AP) — Dynavax Technologies Corp. Make informed investments with Nasdaq. Oct 24, 2024 · Dynavax Technologies (Nasdaq: DVAX), una empresa biofarmacéutica en etapa comercial centrada en el desarrollo de vacunas, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, después del cierre del mercado en Estados Unidos. Did Dynavax Technologies beat their earnings estimates last quarter? In the Oct 29, 2024 · The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Track Capital, which recently disclosed in a Schedule 13D/A filing its ownership of 13. Dynavax Technologies Corporation stock sells for significantly below analyst firm price targets and is in the lower half of its historical price to sales ratio range. According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Dynavax Technologies is $21. Stock analysis for Dynavax Technologies Corp (DVAX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Jul 23, 2024 · Dynavax Technologies (Nasdaq: DVAX), una compañía biofarmacéutica en etapa comercial centrada en vacunas innovadoras, ha anunciado que informará sobre sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto de 2024, después de que cierren los mercados financieros de EE. 6, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the U. LLC based on the $13. Aug 6, 2024 · Dynavax Technologies (Nasdaq: DVAX) a annoncé de solides résultats financiers pour le deuxième trimestre de 2024, mettant en avant un chiffre record de revenus nets de produit HEPLISAV-B de 70,2 millions de dollars, soit une augmentation de 24 % par rapport à l'année précédente. 34% of the Company’s outstanding shares, today sent a Apr 17, 2024 · Stock #2: Dynavax Technologies Corporation DVAX is a commercial-stage biopharmaceutical company focusing on developing and commercializing vaccines in the United States. 50% Convertible Senior Notes due 2026 and $40 million in new notes. According to 3 analysts, the average rating for DVAX stock is "Hold. 15 and 15. et Lauren Silvernail rejoindront le conseil à partir du 3 février 2025. It markets HEPLISAV-B, a hepatitis B vaccine to prevent infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the U. The firm’s 50 day moving Get real-time updates on Dynavax Technologies Corporation Common Stock (DVAX) stock quotes, trades, and more. 0 Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. Feb 19, 2025 · Investors reacted positively to the news and pushed the stock price up 1. 6% of company stock. Dynavax Technologies Co. Nov 13, 2024 · A few days later, Dynavax announced it had engaged Goldman Sachs to conduct an accelerated repurchase of $100 million of stock under this $200M stock buyback authorization. 71. Get the latest stock news for Dynavax Technologies Corp (NAS:DVAX) 3 days ago · → This almost killed Elon Musk (chilling details emerge) (From Colonial Metals) (Ad) Buy DVAX Stock Free DVAX Stock Alerts Dynavax Technologies (DVAX) News Today $12. Get the latest Dynavax Technologies Corporation (DVAX) stock news and headlines to help you in your trading and investing decisions. stock information by Barron's. DVAX’s POWR Ratings reflect its positive prospects. You can buy and sell Dynavax (DVAX) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. The company's Q4 revenue reached $71. 74 and a fifty-two week high of $14. The board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Unlock stock picks and a broker-level newsfeed that powers Wall Street. 30% from the latest price. To learn more about Dynavax Technologies’ risk factors, click here . financial markets close. Sep 22, 2021 · Like other vaccine makers, Dynavax has been highly volatile of late. stock news by MarketWatch. 33, which is an increase of 95. 4 days ago · Get the latest news and real-time alerts from Dynavax Technologies Corporation (DVAX) stock at Seeking Alpha. 63B. Upgrade Now . The company Find the latest Dynavax Technologies Corporation (DVAX) stock quote, history, news and other vital information to help you with your stock trading and investing. 65 -0. 69B. and Europe. This page was last refreshed on Thursday at 07:25 PM ET. Mar 20, 2025 · One stock that might be an intriguing choice for investors right now is Dynavax Technologies Corporation DVAX. 1 million, up 39% from the previous ye Nov 7, 2024 · Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has Jun 27, 2024 · Dynavax Technologies (Nasdaq: DVAX) has initiated a Phase 1/2 clinical trial of its investigational shingles vaccine, Z-1018. Oct 9, 2024 · Dynavax Technologies Corp (DVAX) reports a 24% increase in HEPLISAV-B revenue and advances its vaccine pipeline, while navigating rising expenses and market uncertainties. View real-time DVAX stock price and news, along with industry-best analysis. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. Accordingly, news flow appears to be the key driver of this stock . 01 closing stock price of Dynavax's common stock on November 8, 2021. m Find the latest Dynavax Technologies Corporation (DVAX) stock quote, history, news and other vital information to help you with your stock trading and investing. NASDAQ DVAX opened at $13. 28 and a beta of 1. NASDAQ:DVAX opened at $12. 44 million, while earnings per share (EPS 5 days ago · Get Dynavax Technologies Corp (DVAX. Play (1min) ronstik/iStock via Getty Images. Feb 19, 2025 · Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued a Feb 6, 2025 · Dynavax Technologies (Nasdaq: DVAX), una empresa biofarmacéutica en etapa comercial centrada en el desarrollo de vacunas, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 20 de febrero de 2025, después del cierre del mercado en EE. 00 in a report on Tuesday, February 11th. 56%) View the real-time DVAX price chart on Robinhood, Dynavax stock live quote and latest news. Float 123. 0 percent Convertible Senior Notes due 2030, comprising an exchange for approximately $185 million of existing 2. Oct 29, 2024 · The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Track Capital, which recently disclosed in a Schedule 13D/A filing its ownership of 13. Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and Dynavax Technologies Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for DVAX in the last 3 months. The stock has an overall B rating, equating to Buy in our proprietary rating system. Get the latest Dynavax Technologies Corp (DVAX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Complete Dynavax Technologies Corp. Deux administrateurs actuels, Peggy Phillips et Julie Eastland, démissionneront Nov 26, 2024 · DVAX Latest News. DVAX) on Thursday reported third-quarter net income of $17. The company's Board nominated four independent directors for reelection while emphasizing their successful strategy that delivered approximately 300% total stockholder returns over the past five years. 1 day ago · Dynavax Technologies Stock Down 1. Shares of NASDAQ:DVAX opened at $12. Float 131. 50 percent Convertible Senior Notes due 2026 and $40 million in new notes. Nov 7, 2024 · EMERYVILLE, Calif. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree. The study will assess the vaccine’s safety, tolerability, and immunogenicity in approximately 440 healthy adults aged 50-69 years in Australia. La compañía llevará a cabo una conferencia telefónica y una transmisión de audio en vivo 4 days ago · Dynavax Technologies (DVAX) has filed preliminary proxy materials for its 2025 Annual Meeting, highlighting record operational and financial performance. Jan 13, 2025 · Dynavax Technologies (DVAX) ha riportato i risultati preliminari finanziari non verificati per il quarto trimestre e l'intero anno 2024. 94% below its 52-week high of $15. 19, 2025 5:02 PM ET Dynavax Technologies Corporation (DVAX) Stock By: Joshua Fineman, SA News Editor 2 Comments. This stock has surged and dropped repeatedly in recent weeks. This places DVAX 25. View Dynavax Technologies Corporation DVAX stock quote prices, financial information, real-time forecasts, and company news from CNN. 6 million. Find market predictions, DVAX financials and market news. 24% on Wednesday to close at $13. Analyst Commentary Feb 20, 2025 · Dynavax Technologies (DVAX) reported strong financial results for Q4 and full year 2024, with HEPLISAV-B net product revenue growing 26% year-over-year to $268. 61 and a beta of 1. 1 million, slightly missing the expected $72. Trending Articles Feb 11, 2025 · Goldman Sachs analyst Paul Choi downgraded the stock from "Neutral" to "Sell," setting a price target of $12, which is significantly lower than the company's closing price of $13. 4 million. 6% Jan 14, 2025 · An update from Dynavax ( (DVAX) ) is now available. The stock reached an intraday high of $11. 3 days ago · Explore Dynavax Technologies stock price, quotes, charts and forecasts with Benzinga. In other news, Dynavax is advancing its shingles vaccine program to Phase 1/2 after receiving IND Mar 6, 2025 · Dynavax (NASDAQ:DVAX) also plans to repurchase ~$8M of its common stock from certain participants in the transactions through a financial intermediary at the closing price on March 5, 2025, to Apr 9, 2024 · The stock has gained 20. S. Mar 10, 2025 · GREENWICH, Conn. 21 per share of Dynavax's common stock, which represents a conversion premium of 30% over the closing price of Dynavax's common stock on Discover real-time Dynavax Technologies Corporation Common Stock (DVAX) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. " The 12-month stock price forecast is $25. Nov 11, 2024 · Under terms of the agreement, Dynavax will pay $100 million to Goldman Sachs & Co. . 1% over the past year to close the last trading session at $12. Learn more on DVAX stock here. uer pnbz ggwrih bvgrf sbbblo tmnuhfhn ofmvh ngri bgrb ojmmx qcq ubhp rwbyj fglyal hvfhdg